Durability of Response to Treatment among Antiretroviral‐Experienced Subjects: 48‐Week Results from AIDS Clinical Trials Group Protocol 359

Autor: Jon Cook, Charles B. Hicks, Bruce Coon, Richard Hutt, Margaret A. Fischl, David Pearson, Jan Clark, Candida T. Talabucon, Carol L. Brosgart, Joan Dragavon, Laura Ponticello, Janet Devine, Eugene Sun, Melissa Kerkau, Daniel C. Rodrigue, Donna Thee, Jeanne Berg, Mario Guerrero, Lyle Oshita, Jane L. Norris, Judy Aberg, Mark I. Becker, John Fuchs, Pablo Tebas, Guillermo J. Vázquez, Pamposh Kaul, Antoinette Kenton, Phyllis Barnett, Pascal J. de Caprariis, Michael Royal, Michelle Jack, Ann Walawander, Harold A. Kessler, Scott Souza, Sharon Shriver, Genice Hamilton, Susan E. Cohn, Hailong Cheng, John G. Gerber, Monica Millard, Sherree Wright, Linh Ngo, Gildon N. Beall, Debra Ogata-Arakaki, John Mc Neil, David M. Mushatt, Courtney V. Fletcher, Charles van der Horst, Karen Waterman, Ileana Lopez, David Katzenstein, Robert J. Fass, Joseph J. Eron, Edward P. Acosta, Stephen W. Lagakos, Hilda Mendoza, Jim Bruce, Michael F. Para, Sally Snyder, Mary Shoemaker, Mark A. Beilke, Tammy Powell, Margaret Nelson, Juan J.L. Lertora, Liliana Aguinada, Virginia Ramirez, M. Graham Ray, William W. Freimuth, Brenda Greenhill, Beverly Putnam, Aouie Carrera, Mary Albrecht, Michael F. Giordano, Stuart Carr, John M. Leedom, Charlotte Mills, Charles J. Gonzalez, Rebecca Becker, Richard Haubrich, Elizabeth Gimbel, D. Baker, Vivian Yuan, Andrea Weiss, Hongyu Jiang, Cheryl N. Karol, Kim Ingersol, Russell Strada, Paulette Mac Dougall, Carla Pettinelli, Glenna M. Auerback, Alice F. Mercado, Frances Canchola, Chris Helker, Susan A. Fiscus, X. Joan Hu, Janine R. Maenza, Henry S. Sacks, Robert Kalajian, Debbie Slamowitz, Robin Shepard, Margo Heath-Chiozzi, Michael J. Borucki, Ana Martinez, Olivia T. Ortiz, Suzanne Fiorillo, Jorge Santana, Michael S. Saag, Dena Duran, Steve Nowling, Jeff Taylor, Kristine Todd, Robert W. Coombs, Douglas D. Richman, Thomas C. Merigan, Robert Delapenha, Kenneth Wood, Harvey M. Friedman, Joseph Pulvirenti, Don Craven, Timothy W. Schacker, Ronald Swanstrom, Neel French, Judith Feinberg, Mark A. Jacobson, Judith Brown, Joseph Wheat, Ross G. Hewitt, James F. Rooney, Scott A. Smith, Bruce Peel, Doris Shank, Lisa Alexis, Roy M. Gulick, Andrea Christopher Belschner, Linda Meixner

Publikováno v: The Journal of Infectious Diseases. 186:626-633

The 24-week extension of AIDS Clinical Trials Group Protocol 359, a study of human immunodeficiency virus (HIV)‐infected, indinavir-experienced patients, was designed to study the durability of “salvage” treatment regimens. Patients received sa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cca3b1c2613fffeb024856928c7b68a2
https://doi.org/10.1086/342681

Combination Therapy with Efavirenz, Nelfinavir, and Nucleoside Reverse-Transcriptase Inhibitors in Children Infected with Human Immunodeficiency Virus Type 1

Autor: David M. Kornhauser, Harold W. Lischner, Stuart E. Starr, Mark I. Becker, Bobie Graham, Richard C. Brundage, Suzanne Siminski, Stephen A. Spector, William D. Fiske, Merril Gersten, Florence H. Yong, Lynette Purdue, Wayne M. Dankner, Carol Vincent, Terence Fenton, Patricia M. Flynn, Douglas J. Manion, Nancy M. Ruiz, James McNamara, Courtney V. Fletcher, Lynne M. Mofenson

Publikováno v: New England Journal of Medicine. 341:1874-1881

Background Consistent long-term viral suppression has been difficult to achieve in children with human immunodeficiency virus type 1 (HIV-1) infection. We tested the safety and antiviral efficacy of a novel combination consisting of efavirenz, nelfin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c1a752ceb6146e9fcb47c980d26b5cd8
https://doi.org/10.1056/nejm199912163412502

Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection

Autor: Debra Benator, Claudia Silva-Trigo, Brenda E. Jones, Poe Hirr Hsyu, Zhen A. Zhao, Marc H Weiner, Melissa Engle, William J. Burman, Charles A. Peloquin, Laurie Sandman, Mark I. Becker, Awal Khan, Andrew Vernon

Publikováno v: Pharmacotherapy. 27(6)

Study Objective. To characterize the bidirectional interaction between twice-daily nelfinavir and twice-weekly rifabutin and isoniazid in patients with tuberculosis and human immunodeficiency virus (HIV) infection. Design. Prospective cohort study. S

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f15be12f5704393cc42023550f7b719
https://pubmed.ncbi.nlm.nih.gov/17542762

Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants

Autor: Dianne Holland, Paula Britto, John L. Sullivan, Mark I. Becker, Elizabeth Smith, Bobbie Graham, Lynne M. Mofenson, Edmund V. Capparelli, Katherine Luzuriaga, James D. Connor

Publikováno v: Scopus-Elsevier

Nelfinavir dosed at approximately 20 to 30 mg/kg three times a day (TID) in older children provides exposure similar to 750 mg TID in adults. However, the pharmacokinetics (PK) of nelfinavir in infants who are2 years of age is not well-described. The

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3bb9be91e9c80ae5d09988cd4821ae3
http://www.scopus.com/inward/record.url?eid=2-s2.0-0034892679&partnerID=MN8TOARS